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ABSTRACT 
The Role of Protein Kinase C Epsilon on Hydrogen Peroxide and Nitric Oxide Release 
during Oxidative Stress caused by Extracorporeal Shock Wave Lithotripsy 
 
Clinical extracorporeal shock wave lithotripsy (ESWL) treatment to ablate kidney stones 
can cause acute damage to the renal microvasculature. Accumulation of continued 
treatment with shockwave therapy can lead to chronic damage to the kidney, and lead to 
clinical hypertension. Shockwaves have been shown to stimulate endothelial cells to 
release superoxide (SO), which is converted to hydrogen peroxide (H2O2), and reacts 
with nitric oxide (NO) to produce peroxynitrite anion (OONO
-
), creating a powerful 
oxidant that increases oxidative stress while simultaneously reducing NO bioavailability. 
Increased oxidative stress during events such as ESWL, also uncouples NO production 
reaction in endothelial nitric oxide synthase (eNOS), causing eNOS to produce SO 
instead of NO, exacerbating the oxidative insult. NO is an essential signaling molecule 
responsible for vasodilation, which also functions in inhibiting platelet adhesion and 
reducing leukocyte-endothelial interactions. This increased oxidative stress, decreased 
NO bioavailability, and the direct physical force of the shock wave causes prolonged 
renal vasodilation and eventually vascular endothelial dysfunction in the renal 
vasculature. Protein kinase C epsilon (PKC-ε) positively regulates eNOS, increasing its 
activity regardless of whether eNOS is producing SO or NO. We hypothesized that the 
PKC-ε peptide inhibitor (N-Myr-EAVSLKPT, MW = 1054) would attenuate ESWL-
induced increased H2O2 release and increase NO release compared to ESWL-saline 
control rats, while the PKC-ε peptide activator (N-Myr-HDAPIGYD, MW 1097) would 
increase ESWL-induced H2O2 release and reduce NO release. H2O2 and NO was 
iv 
 
                                                                             
measured in real-time by inserting a H2O2 or NO microsensor (100 um diameter) into the 
left renal vein in anesthetized male Sprague-Dawley rats. ESWL treatment was 
administered with 16 kV shock waves for 13 minutes in a period of 500 shocks at 60 
beats/min then 500 shocks at 120 beats/min by an Epos Ultra lithotripter. Immediately 
post-ESWL treatment, saline or drug was infused through the external jugular vein. 
Infusion of PKC-ε inhibitor in ESWL-treated rats significantly reduced H2O2 release (n = 
5) from 5 minutes (p < 0.05) to 30 minutes (p < 0.01) compared to ESWL-saline controls 
(n = 5). PKC-ε inhibitor also significantly increased NO release (n = 5) from 5 minutes (p 
< 0.01) to 30 minutes (p < 0.01) compared to ESWL-saline controls (n = 5). Contrary to 
the hypothesis that PKC-ε activator would increase H2O2 release and reduce NO release, 
results from PKC-ε activator showed a similar but not statistically significant different 
trend to ESWL-saline controls in H2O2 release (n = 5) and NO release (n = 5). The data 
shows that inhibition of PKC-ε effectively decreases ESWL-induced increased H2O2 
release and significantly restores NO release, which suggests that uncoupled eNOS is a 
significant source of oxidative stress during ESWL treatment. This results in decreased 
oxidative stress, attenuating endothelial dysfunction and further damage to the renal 
microvasculature. 
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INTRODUCTION 
Extracorporeal shock wave lithotripsy, or ESWL, is an effective, non-invasive 
therapy utilized to fragment stones in the kidney and urinary tract. Lithotripsy 
provides a less detrimental alternative to invasive treatments, which can lead to 
parenchymal fibrosis in the kidney
37
, permanently damaging the delicate structure of 
numerous nephrons. A lithotripter generates high-energy acoustic pulses and 
propagates those shockwaves through a lens that focuses on the location of the stone, 
breaking up the stone. After treatment, fragmentation of the stone allows the debris to 
be cleared by the flow of the urinary tract. Although ESWL provides a safer solution 
to removing harmful stone, the forces fragmenting the stone can also cause 
underlying damage to vascular endothelium due to increased oxidative stress, acute 
damage not easily detected. ESWL treatment can not only lead to damage from the 
physical forces of the shock waves, but oxidative stress indirectly caused by shock 
waves, which can lead to acute injury post-treatment and may lead to chronic adverse 
effects. This endothelial dysfunction can be attenuated pharmacotherapeutically by 
signaling the endothelium to reduce release of reactive oxygen species, such as 
superoxide (SO) and hydrogen peroxide (H2O2). 
 
 
Limitations of ESWL 
 
 Lithotripsy remains the only non-invasive technique available in the removal 
of stone, however; the treatment does not come without its limitation. Over the past 
couple decades, urologists have scrutinized the ESWL treatment and its usage has 
been restricted over concerns of efficacy of stone fragmentation and safety of the 
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procedure. A major limitation to lithotripsy that has dictated procedure is the stone 
burden, which includes the stone size and the stone type
32
. Because of the limited 
capacity of the kidney and ureters to clear debris, shock wave lithotripsy is generally 
regarded as the primary method for treatment if the stone is 2.5cm or smaller and 
there are no abnormalities in the patient’s renal anatomy32.  Certain stone types may 
be resistant to shock wave lithotripsy, among them brushite, calcium oxalate 
monohydrate, and cysteine stones or may be easily fragmented but not completely 
comminuted, leading to re-treatment 
32
. Stones treated with lithotripsy are ultimately 
broken up by two forces: a positive pressure phase, in which the direct force of the 
shock wave compresses the stone and a negative pressure phase, which causes 
cavitation bubbles to form and collapse near the stone. Low-energy shock waves are 
sufficient enough to break up the stone, however, higher-energy shock waves are 
needed to create an energy scattering effect caused by the accumulation of stone 
fragments from the initial shock waves
35
. Stress waves and cavitation have been 
shown to work in a synergistic manner in ESWL
35
. Unfortunately, the stress forces 
not only break up the stone, but also attribute to ESWL-induced injury. Intraluminal 
bubbles formed from cavitation have been linked to damage and rupturing of blood 
vessels
35
.  
The greatest concern of the safety of lithotripsy grew from animal and clinical 
studies showing lesions from shock waves involving ruptured blood vessels that 
would cause intraparenchymal hemorrhage and renal
35
. Damage from shock waves 
were found to be dose-dependent, according to the number and the amplitude of 
ESWL, and localized, but not limited to the focal zone of the lithotripter
32
. Research 
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has shown that these injuries can rupture primarily in blood vessels, which in turn 
causes bleeding leading to inflammatory responses that damage functional renal 
tissue
32
. These injuries from ESWL, although not directly proven to be the cause of 
chronic disease, do promote concern and has stimulated the investigation that has 
generated much support that patients, especially though who have had multiple 
lithotripsy treatments, have an increased risk to developing hypertension and diabetes 
mellitus
32
. 
 
 
Improvements to ESWL Technique 
 
Ongoing research has intensely studied the implications of ESWL-treatment 
protocols in order to determine the safety parameters as well as the highest efficacy 
within those parameters. To determine safer strategies, researchers have investigated 
factors such as number of shock waves delivered, frequency of shock wave 
administration, energy output of shock waves, step-wise change and constant energy 
output, and pretreatment protocols
32
. Ultimately, the primary goal was to complete 
stone comminution with the least amount of shock waves at the lowest possible 
power setting and slowest rate of delivery
32
. The results of research have shown many 
beneficial changes to the treatment protocol, which is a non-standardized procedure. 
Researchers used 2000 shock waves at above 20kV energy output and at a constant 
rate of 120 shock waves per minute (sw/min) to simulate a general lithotripsy 
procedure. Utilizing this procedure, the quick, powerful, and numerous shock waves 
would yield easily quantifiable trauma to kidney tissue
32
. Adjusting the rate to slower 
frequencies proved to significantly reduce the damage from ESWL, even at the same 
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energy output, showing significantly better treatment at 60 sw/min compared to the 
typical 120 sw/min
32
. In a separate study, increasing the energy output from lower 
levels in a step-wise fashion increased stone comminution without changing any other 
parameters, while a decreasing or constant energy output yielded poorer clearance
35
. 
A protective effect was observed in the kidney when a low frequency, lower 
energy output pretreatment of 100 shocks was given before the treatment phase. 
Results from this study showed that the initial exposure to shock waves resulted in a 
vasoconstrictive response during the shock wave delivery, rather than a 
vasoconstrictive response post-ESWL treatment seen in the standard procedure
32
. 
This observation has led to the conclusion that the protective effect from pretreatment 
lies in the vasoconstriction of renal vasculature during incoming shock waves. 
Although inconclusive, there has been some speculation to the mechanism behind 
protective vasoconstriction. Low pressure from shock waves at low output voltages 
may cause vessels to vasoconstrict and reduce intraluminal volume of blood, thus 
lowering the number of potential cavitation bubble nuclei, protecting against the high-
pressure phase of the shock waves
35
. Another theory suggests that the 
vasoconstriction itself strengthens the integrity of the vasculature to prevent vessel 
rupture. With these developments, researchers were able to devise a new, current 
standard that provides better treatment with less injury and effective stone 
comminution, recommending a slow rate at increasing energy output from lower –to 
moderate levels, using as few shock waves as necessary
32
. 
Despite improvements to ESWL technique that shows dramatically reduced 
injury, recent research by this laboratory has shown that oxidative stress is increased 
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post-ESWL treatment even under the recommended changes to ESWL procedure. In 
that study, ESWL was shown to induce increases in H2O2 and decreases in nitric 
oxide (NO), characteristics of endothelial nitric oxide synthase (eNOS) dysfunction 
found in ischemia-reperfusion injury. This has led our laboratory to further 
investigate the role of eNOS during oxidative stress caused by ESWL, explore 
mechanisms involved in its regulation, and potentially attenuate the oxidative stress 
through manipulation of eNOS regulation. Treatment of oxidative stress in the 
vascular endothelium may be pivotal in preventing underlying acute injury that leads 
long-term damage to kidney tissue.  
 
Endothelium and Nitric Oxide 
Endothelium is the pivotal barrier between the cardiovascular system and the 
entire body. Continued maintenance of proper endothelium function is essential for 
not only the physical barrier the endothelium provides, but also for vascular 
homeostasis. Endothelial cells (ECs) effectively form a semipermeable barrier 
throughout the entire vasculature and control molecular transfer between the blood 
and tissue.  This layer of cells, capable of paracrine and endocrine function, can sense 
the dynamic changes of blood and regulate vascular tone. ECs can release 
vasoconstrictors, such as endothelin-1 and prostaglandins H2, or vasodilators, 
prostacyclin, endothelium-derived hyperpolarizing factor, and most importantly, 
nitric oxide (NO). NO serves as a primary vasodilator, relaxing smooth muscle cells, 
and also provides anti-thrombotic, anti-atherosclerotic, anti-inflammatory functions 
for the endothelium
29
.  
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Long-term levels of arterial pressure can be regulated by the medullary blood 
flow of the kidney. Reductions of 15-30% to renal medulla blood flow have been 
shown to lead to hypertension
13
. Essentially, NO has an important role in the 
regulation of medullary blood flow, which regulates arterial blood pressure and 
sodium homeostasis. NO acts in low renal vascular resistances and stimulates 
natriuresis and dieresis regardless of the renal perfusion pressure
13
. Studies show that 
NO can reduce sodium reabsorption in most tubular segments, notably the proximal 
and distal tubules, thick ascending limb, and cortical collecting ducts
13
. NO associates 
tubular metabolic needs to blood flow and protects the medulla from underperfusion 
and macula densa NO acts as tubuloglomerular feedback control of afferent arteriolar 
resistance in the regulation of renal blood flow
13
. 
Studies have shown that NO can limit platelet adhesion and leukocyte-
endothelial interactions by inhibiting exocytosis of inflammation-inducing granules 
within endothelial cells via targeting N-ethylmaleimide sensitive factor through S-
nitrosylation of exocytic machinery
33
. By decreasing granule trafficking to the cell 
membrane and accelerating endocytosis, NO regulates the transport of leukocyte-
endothelial interacting proteins and inhibits leukocyte interaction with the EC 
membrane. In this effect, NO decreases expression of P-selectin on the EC surface, 
the transmembrane protein responsible for leukocyte rolling, when ECs loosely attach 
to leukocytes upon P-selectin glycoprotein ligand-1 on their surfaces interaction with 
P-selectins
33
. Additionally, integrins and intercellular adhesion molecule expression is 
decreased by NO
33
. NO works antagonistically to inflammatory signals that activate 
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the exocytosis of resting EC granules to translocate to the cell membrane that lead to 
inflammatory responses
33
. 
 
 
The Structure and Function of eNOS 
eNOS is the primary producer of nitric oxide along the endothelium of the 
cardiovascular system. eNOS, also known as NOS3,  is one of three nitric oxide 
synthases, and different palmitoylation and myristoylation sites for subcellular 
targeting from other NOS isoforms. Although functionally primarily localized within 
caveolae distributed through the EC surface, eNOS is a dynamic protein, which is 
also found inside the Golgi apparatus and the plasma membrane
20
. The enzyme 
consists of two identical monomer units with a dual domain, a flavin-reductase 
domain and heme-oxygenase domain, connected together by a calmodulin-binding 
peptide
40
. The flavin-reductase domain consists of a NADPH oxygenase, FAD, and 
FMN subunits, while the heme-oxygenase domain contains a prosthetic heme group 
and a binding site for pterin molecules
45
. The two monomers are held together by a 
zinc-tetrasulfate bond, contributed by two cysteine residues from each monomer
30
. 
This bond is critical to maintaining the homodimer structure and can be subject auto-
inhibition by oxidation or S-nitrosylation that will dissociate the structure into 
monomers when levels of NO or H2O2 become too high
17
. 
In order for eNOS to undergo its catalytic activity, the two monomers must 
form a homodimer. This functional configuration is maintained by the presence of 
pterin molecules located adjacent to the heme group.  eNOS also requires the Ca
2+
-
dependent binding of calmodulin to the calmodulin-binding peptide. Upon binding of 
calmodulin, eNOS can conduct its catalytic activity. Physiologically, BH4 is the 
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necessary pterin cofactor required by eNOS not only for the production of NO and 
but also the stability of the homodimer through numerous hydrogen bonds. eNOS 
produces NO the catalysis of a two-step reaction sequences that requires BH4 cofactor 
for both steps as an electron donor. The first of the two reactions is the oxidation of 
the substrate, L-arginine, to the stable intermediate N-hydroxy-L-arginine followed 
by the oxidation of the intermediate to yield NO and L-citrulline. These two reactions 
depend on an electron flow from the oxidation of NADPH to FAD, then FMN, 
ultimately to O2, which is bound to the iron-heme group, forming a ferrous-dioxygen 
complex
53,65
. 
 
eNOS Coupling and Uncoupling 
Not only is eNOS a primary producer of NO, eNOS can also change its 
enzymatic profile to produce SO (Figure 1). BH4 competes with another physiological 
pterin, BH2, for the cofactor binding site. When BH2 replaces BH4 in the cofactor 
binding site, the transfer of electrons from the reductase domain to the oxygenase 
domain is uncoupled
64
.Without BH4 to facilitate the electron transfer, molecular 
oxygen sequesters an electron from the heme group it is bound to, dissociating from 
the heme-dioxygen complex as SO. With a similar structure to BH4 without its 
catalytic capabilities, BH2 may stabilize the catalytic homodimer to produce SO. SO 
has a relatively short half-life, but has an extremely large reactivity constant with NO. 
SO produced from eNOS is thus capable of quenching NO also produced from eNOS, 
which leads to the formation of the highly reactive peroxynitrite anion (ONOO
-
). The 
scavenging of NO by SO to produce ONOO
-
 decreases NO bioavailability and causes 
further oxidative stress, leading to more eNOS uncoupling, as well as damaging the 
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cell. ONOO
-
 contributes greatly to oxidative stress by targeting its limited number of 
biological targets. Because of a high in vivo concentration of CO2 reacting with 
ONOO
-
 at a fast rate, many molecules do not compete with ONOO
-
 before its 
conversion to bicarbonate
14
. However, ONOO
-
 is capable of oxidizing BH4, leading 
directly to eNOS uncoupling
2
. ONOO
-
 oxidizes BH4 to BH2, with a reaction order 
much higher than ONOO
-
 with ascorbate, glutathione, or thiol groups
28
. Although SO 
can also react with BH4, the rate for this reaction is much slower than its scavenging 
of NO
63
. Therefore, as the product of SO scavenging of NO, ONOO
-
 is the likely 
oxidant for BH4 oxidation and the direct contributor to the oxidative stress that leads 
to eNOS uncoupling, further exacerbating oxidative stress caused by eNOS
21, 58
. 
ONOO
-
 can also target heme-containing proteins and proteins containing zinc-thiolate 
centers, oxidizing bonds and destabilizing their protein structure. eNOS falls into both 
these categories, showing that it is a readily available target for destabilization, which 
may in turn allow for oxidation of bound BH4 or replacement of BH4 with BH2. BH2 
competes for the pterin-binding site in eNOS with similar affinity, allowing a free 
exchange of the two pterin molecules which may be dependent upon the 
concentration ratio of the two molecules within the cell. 
10 
 
                                                                             
 
 
Figure 1. eNOS Enzymatic Profiles: Coupled State and Uncoupled State. eNOS 
is a homodimer with three domains: an oxygenase domain, reductase domain, and 
calmodulin-binding domain. In eNOS, electrons from NAPDH are shuttled to the 
ferrous-dioxygen complex. The BH4 cofactor donates an electron to couple oxygen 
reduction with L-arginine oxidation in the ferrous-dioxygen complex to produce NO. 
During oxidative stress, BH4 is oxidized to BH2, thereby increasing BH2 to BH4 ratio. 
In the presence of BH2, eNOS is unable to utilize electrons from BH2, uncoupling 
oxidation of L-arginine from oxygen reduction, causing the ferrous-dioxygen 
complex to produce SO instead of NO. 
 
 
Protein Kinase C and the Epsilon Isoform 
 
One of the discovered regulatory mechanisms of eNOS is through the signal 
transduction cascade of protein kinase C. Protein kinase C consists of serine/threonine 
protein kinase family complete with three classes of 11 different isozymes, which are 
expressed in many cell types, which include polymorphonuclear leukocytes (PMNs) 
and vascular endothelial cells
5,73
. Each isoform has the ability to directly regulation 
eNOS through phosphorylation at specific residues. The effects of each isoform vary; 
some may phosphorylate to enhance eNOS activity, or inhibit its function
41
.Protein 
kinase C epsilon (PKC-ε) in particular is constitutively expressed in vascular 
endothelial cells and not in PMNs and increases eNOS activity via phosphorylation at 
serine residue 1177
74
. 
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PKC enzymes consist of two domains, the N-terminal regulatory domain with 
C1 and C2 subdomains, and the conserved C-terminal catalytic domain. C1 and C2 
subdomains act as mediators between PKC and secondary messengers and 
interactions with other cellular molecules
5
. Cell permeable peptides due to 
myristoylation can be used as activators or inhibitors to eNOS activity. For PKC-ε, 
these peptides are derived from the C2/V1 domain of the regulatory region of PKC-ε 
and are capable of directly modulating PKC-ε activity when within the cell, thus 
indirectly regulating eNOS
5
. PKC-ε activator peptide activates PKC-ε by targeting its 
receptor for activated C kinase (RACK) region, which facilitates the translocation of 
PKC-ε in the cytosol to the cell membrane where the enzyme will phosphorylate 
eNOS. Activator peptide interferes with the PKC autoinhibitory intramolecular 
interactions, allowing for its activation
5
. On the other hand when PKC-ε inhibitor 
peptide binds to RACK, it interferes with the protein and PKC-ε translocation to the 
cell membrane is inhibited, preventing phosphorylation of eNOS, thus decreasing its 
activity. In ischemia-reperfusion models involving the heart, PKC-ε activator has 
shown to be cardioprotective through preconditioning, but damaging to heart tissue 
during reperfusion, which may be due to enhanced activity of uncoupled eNOS, 
leading to an increase in SO release
61
. On the contrary, PKC-ε inhibitor has resulted 
in cardioprotective effects during reperfusion, decreasing uncoupled eNOS activity, 
decreasing SO release and improving NO bioavailability
61
. 
12 
 
                                                                             
 
Figure 2. Sources of Oxidative Stress and Effects of PKC-ε Activator and 
Inhibitor.  (1) NADPH Oxidase releases SO (O2
-∙) from leukocytes and endothelial 
cells; (2) Mitochondria releases SO via incomplete oxidative phosphorylation; (3) 
Uncoupled eNOS releases SO in the presence of BH2 . Increased SO quenches NO 
produced from coupled eNOS, reducing NO bioavailability and further increases 
oxidative stress through peroxynitrite (ONOO
-
). PKC-ε activator/inhibitor peptides 
increase/decrease coupled and uncoupled eNOS activity, respectively.  
 
 The previous study by this laboratory using the ESWL model investigated the 
effects of ESWL on NO and H2O2 levels and experimented with regulation from 
another PKC isoform, PKC-βII. Their studies showed that ESWL results in an 
increase in H2O2 release as well as a decrease in NO, confirming ESWL-induced 
oxidative stress after lithotripsy treatment. Using PKC-βII inhibitor, PKC-βII activity 
was attenuated, which preserved NO bioavailability by preventing the activation of 
SO producer, NADPH oxidase by PKC-βII26. In this study, we will again test the 
effects of ESWL on NO and H2O2 release, and target PKC-ε in an effort to identify if 
eNOS is the primary source of oxidative stress in the renal vasculature and explore 
the effects of PKC-ε regulation through PKC-ε activator and inhibitor peptides on 
ESWL-induced oxidative stress.
13 
 
                                                                             
 
HYPOTHESIS  
 This project will study the implications of ESWL on the release of H2O2 and 
NO in rat renal veins and the changes of this release by the effects of PKC-ε activator 
(N-Myr-HDAPIGYD, MW=1097, Genemed Synthesis, San Antonio, TX) and 
inhibitor (N-Myr-EAVSLKPT, MW=1054, Genemed Synthesis) peptides on the 
enzyme and its role on eNOS. 
 
Effects of ESWL on NO and H2O2 Release Compared to No-ESWL Controls 
 
 Introduction of ESWL treatment will increase H2O2 release and decrease NO 
release compared to controls not treated by ESWL. The stress from the shear forces 
of ESWL will damage endothelium, stimulating H2O2 release while dropping NO 
bioavailability. The non-ESWL treatment group, or sham group, will not experience 
any deviation from baseline release levels. 
 
 
PKC-ε Activator Effects on NO and H2O2 Release 
 
 Infusion of PKC-ε activator will trigger further eNOS uncoupling, increasing 
H2O2 release while simultaneously decreasing NO release. PKC-ε activator will 
indiscriminately activate both coupled eNOS and uncoupled eNOS, increasing both 
NO release and H2O2 release. However, oxidative stress induced by ESWL oxidize 
BH4 to BH2, and will set up increased uncoupling of eNOS thereafter leading to 
increases levels of H2O2 release and decreased levels NO release. 
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PKC-ε Inhibitor Effects on NO and H2O2 Release 
 
 PKC-ε inhibitor infusion after ESWL will attenuate H2O2 release and lessen 
the decrease of NO release. PKC-ε inhibitor, as with activator, will inhibit both 
coupled eNOS and uncoupled eNOS, attenuating both H2O2 release and NO release. 
Since more eNOS are uncoupled after ESWL treatment, inhibition of eNOS will 
cause a greater effect in attenuating H2O2 while allowing NO bioavailability to 
remain less affected by ESWL. 
 
15 
 
                                                                             
METHODS 
 
Measurement of NO and H2O2 Release from Rat Renal Veins post-ESWL 
Treatment 
 Each rat was anesthetized with an induction dose of sodium pentobarbital 
(60mg/kg) via intraperitoneal injection. A maintenance dose (30mg/kg) was delivered 
at intervals of 45 minutes unless otherwise necessary. The rat was then placed on the 
operating table with the left kidney positioned within the range of the lithotripter’s 
focal point and injected intraperitoneally with 1 milliliter (mL) sodium heparin (1000 
USP units/mL). A 24-gauge catheter was inserted into the external jugular for drug 
infusion after ESWL treatment. The animal was then subjected to a mid-line 
laparotomy and the left renal vein was isolated.  
Upon catheterization of the left renal vein with a 22-gauge angiocatheter, the 
microsensor was inserted through the catheter and connected to the free radical 
analyzer. The free radical trace was recorded until a decrease of one picoamp (pA) 
per second, indicating a stable baseline. After the establishment of a baseline, ESWL 
treatment was induced by a total of 1000 shocks in two periods of 500 shocks. The 
first low-frequency period included 500 shocks at 60 beats per minute followed by 
the high-frequency second period of 500 shocks at 120 beats per minute, resulting in 
approximately 13 minutes of shockwave treatment
67
. Immediately post-ESWL 
treatment, 0.5mL saline or drug bolus was infused through the jugular vein followed 
by 0.5mL of saline as a flush. Recordings were taken at the beginning and end of 
treatment, then every five minutes until 30 minutes post-treatment. 
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Animal Model 
The Institutional Animal Care and Use Committee of the Philadelphia College 
of Osteopathic Medicine approved the animal protocol performed in this study. Male 
Sprague-Dawley rats (275-325 grams, Ace Animals, Boyertown, PA) were used for 
all experiments. 
 
Experimental Apparatus 
 During the experiment, free radical concentration data was recorded and 
analyzed by a TBR 4100 Free Radical Analyzer (World Precision Instruments, 
Sarasota, FL). Only one microsensor, H2O2 or NO, was connected to the free radical 
analyzer via a via an interface inside the microsensor cable handle and the free radical 
analyzer linked with a computer to an analytical program, DataTrax2 (World 
Precision Instruments, Sarasota, FL), which read and recorded the data. A Dornier 
Epos Ultra HE (high-energy) lithotripter transmitted the ESWL treatment with shock 
waves at intensity level 13 (16kv), the maximum for this model of lithotripter.  
 
Microsensor Calibration 
  Each microsensor was calibrated before each experiment to calculate a 
standard curve, which provided an accurate and consistent response to translate data 
across different animals. Traces were recorded from electrical responses in picoamps 
and translated into molar concentration in vivo. The standard curve was generated by 
a stepwise dose-response of the microsensor to the appropriate standard solution.  
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Since there are no sensors to directly measure SO, H2O2 microsensors were 
used instead. Superoxide dismutase present in cells catalyzes the conversion of SO 
and hydrogen ions to H2O2, thus H2O2 was measured to gauge SO release. The H2O2 
standard solution, a 1.0mM H2O2 solution in deionized water was prepared while the 
reference tip was submerged in a 10mL 0.01M PBS (phosphate buffered saline) 
solution until the registered trace reached a stable baseline. Doses of 2.5μL, 5μL, 
10μL, and 20μL of 1mM H2O2 were added stepwise to record the H2O2 standard 
curve. 
For the NO microsensors, 50mL aqueous solution with solutes of 1mg 
ethylene diamine tetraacetic acid and 1.06mg of S-nitroso-N-acetyl-1,1-penicillamine 
(SNAP) was prepared as the NO standard solution. The NO reference tips were 
soaked in 10mL of 0.2M CuSO4·5H2O until baseline, then doses of 1μL, 5μL, 10μL, 
and 20μL the SNAP solution were used to record the NO standard curve. 
 
Treatment and Control Groups  
Each group was exposed to the same number and frequency of shockwaves. 
Only the left renal vein can be sufficiently isolated to insert the catheter, limiting one 
microsensor per experiment and thus only NO or H2O2 could be measured at one 
time. 
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Table A. Treatment and Control Groups 
Group Nitric Oxide (NO) Hydrogen Peroxide (H2O2) 
No-ESWL Control 
(No drug) 
n = 5 n = 5 
ESWL Control 
(1mL 0.9% Saline) 
n = 6 n = 6 
PKC-ε Activator 
(.9mg/kg, 10μM) 
n = 5 n = 5 
PKC-ε Inhibitor 
(.8mg/kg, 10μM) 
n = 5 n = 5 
 
Statistical Analysis 
All data in the text and figures were presented as means ±SEM.  The data for 
each time-point in the recordings were analyzed by ANOVA using post hoc analysis 
with Fischer’s PLSD test for data.  Probability values of less than 0.05 were 
considered to be statistically significant. 
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RESULTS 
 
H2O2 and NO release in Rat Left Renal Vein  
 
 All graphs in this section are measured as relative changes.  A relative change 
graph arbitrarily sets the baseline at 0.  When a drug treated group exhibits decreased 
NO or H2O2 release it is represented as a change from 0 to a negative number on the 
graph. 
 
Figure 3. Real-time Blood NO Changes During Experiment. This graph shows 
change in NO renal vein blood values post-ESWL. ESWL significantly induced a 
70nm decrease in NO release compared to no-ESWL and this effect was significantly 
attenuated by PKC-ε inhibitor. Saline and PKC-ε activator significantly reduced NO 
levels compared to no-ESWL controls (
#p≤0.05, ##p≤0.01). PKC-ε inhibitor 
significantly attenuated the ESWL-induced decrease in NO level (*p≤0.05, **p≤0.01, 
compared to ESWL). 
 
Effects of ESWL, PKC-ε Activator, PKC-ε Inhibitor on NO Release  
The results shown in Figure 3 display the relative changes of NO release 
within the renal vein after 30 minutes of ESWL treatment during the no-ESWL 
control saline control, the ESWL-treated saline control, infusion of PKC-ε activator 
post-ESWL and infusion of PKC-ε inhibitor. In this graph, the ESWL-saline control 
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shows a steeper and prolonged decrease of NO release post-ESWL. ESWL reduced 
NO release levels approximately 70nm compared to the no-ESWL controls. 
Administration of PKC-ε activator resulted in a similar trend to ESWL-saline 
controls, decreasing much more than no-ESWL controls. PKC-ε inhibitor caused a 
counteractive effect against NO decrease from ESWL and attenuated the decrease of 
NO release from ESWL treatment throughout the 30 minutes of the experiment. 
PKC-ε inhibitor appeared to have maintained around 70% of NO release as opposed 
to the saline control. 
 
Figure 4. Real-time Blood H2O2 Changes Relative to Baseline. This graph shows 
change in H2O2 renal vein blood values post-ESWL. ESWL significantly induced a 
750nm increase in H2O2 release compared to no-ESWL and this effect was 
significantly attenuated by PKC-ε inhibitor. Saline and PKC-ε activator H2O2 levels 
significantly rise compared to no-ESWL controls (
#p≤0.05, ##p≤0.01). PKC-ε 
inhibitor significantly attenuated ESWL-induced H2O2 release, lowering levels 
similar to no-ESWL (*p≤0.05, **p≤0.01, compared to ESWL).  
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Effects of ESWL, PKC-ε Activator, PKC-ε Inhibitor on H2O2 Release 
The results shown in Figure 4 display the relative changes of H2O2 release 
also within the renal vein after 30 minutes of ESWL treatment during the no-ESWL 
control saline control, the ESWL-treated saline control, infusion of PKC-ε activator 
post-ESWL and infusion of PKC-ε inhibitor. In this graph, ESWL-saline controls 
maintain a higher level of H2O2 levels post-treatment. ESWL effectively increased 
H2O2 levels approximately 750nm compared to the no-ESWL controls, which showed 
a steady decline over the 30 minute time-course. PKC-ε activator infusion again 
showed similar trend to ESWL-saline controls fluctuating near the levels of the 
ESWL-saline controls. PKC-ε inhibitor significantly reduced H2O2 after ESWL 
treatment through the rest of the experiment. H2O2 levels returned release levels 
similar to no-ESWL controls, negating the effect of ESWL.  
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DISCUSSION 
 
Summary of major findings 
The major findings conclude the results found in the comparison of no-ESWL 
treated rats to ESWL-treated rats and between ESWL-treated saline controls to PKC-ε 
activator and inhibitor groups. In ESWL-treated rats, blood NO decreased while 
blood H2O2 increased compared to no-ESWL controls. This supports our hypothesis 
that oxidative stress and reduced NO bioavailability are induced by ESWL. PKC-ε 
activator was similar to ESWL-saline controls, which may be principally due to 
increased uncoupled eNOS activity. PKC-ε inhibitor significantly attenuated ESWL-
induced effects on H2O2 increase and NO decrease, which may be due to inhibition of 
uncoupled eNOS. 
The effect of ESWL on normal levels H2O2/NO release 
 The results from ESWL treatment on levels of H2O2 and NO release further 
confirmed increased oxidative stress post-ESWL treatment. Levels of H2O2 release 
were increased throughout the 30-minute post-ESWL time-course, while NO levels 
continually decreased after treatment. Even given the current procedure for shock 
wave treatment, oxidative stress still occurs after ESWL delivery. This oxidative 
stress can result in endothelial dysfunction by promoting leukocyte-endothelial 
interactions, thus causing an inflammatory response after ESWL. The decrease in NO 
bioavailability can cause the upregulation of leukocyte adhesion molecules as seen in 
other studies by other research done in this lab
9,10
. The invasion of PMNs into renal 
paremchymal tissue can lead to underlying tissue damage that may cause clinical 
hypertension, especially in patients that undergo multiple lithotripsies
27
. 
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The effect of PKC ε+ on H2O2/NO release following ESWL treatment 
 This study showed that activation of PKC-ε supports and maintains oxidative 
stress caused by ESWL. Although the levels of H2O2 and NO fluctuate during the 
post-ESWL recordings, these fluctuations are statistically insignificant and generally 
follow the trend of ESWL-saline controls. The early rise in H2O2 may indicate 
uncoupled eNOS activity is increasing, while the later drop in H2O2 levels may show 
coupled eNOS returning the balance through increased activity of coupled eNOS. In 
summary, the findings indicate that PKC-ε activator is not protective in oxidative 
stress in ESWL.  
 
The effect of PKC ε- on H2O2/NO release following ESWL treatment 
 PKC-ε inhibitor caused a remarkable effect on H2O2 and NO levels post-
ESWL treatment. Through the inhibition of PKC-ε, H2O2 levels dropped to the no-
ESWL treatment controls, and NO levels increased 60% to 70% compared to ESWL-
saline controls. This indicates an opposing role towards PKC-ε activator, and that 
PKC-ε inhibitor is protective against oxidative stress brought upon by shock waves. 
Regardless of the enzymatic profile, all eNOS activity is inhibited. Because ESWL 
leads to an increase in oxidative stress, the oxidative stress is suggested to increase 
oxidation of BH4 to BH2, leading to increased ratio of BH2-to-BH4 cofactor that 
results in an increased ratio of uncoupled eNOS to coupled eNOS. In this situation, 
uncoupled eNOS outnumber coupled eNOS, producing more SO to quench NO 
bioavailability. Even though when PKC-ε inhibitor is applied all eNOS is inhibited, 
the activity of more uncoupled eNOS is decreased, protecting NO production from 
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coupled eNOS, and the sources, such as hemoglobin and myoglobin reductase, which 
converts plasma nitrites to NO
76
. This allows NO bioavailability to be increased, but 
PKC-ε inhibitor did not completely retain no-ESWL levels of NO bioavailability due 
to the nature of the inhibition. PKC-ε inhibition indiscriminately leads to a reduction 
of eNOS activity and does not selectively inhibit uncoupled or coupled eNOS. Even 
with the decrease in coupled eNOS activity, NO bioavailability remains 700nM 
higher than ESWL-saline control levels after the 30-minute recording, preserving 
critical NO levels even after shock wave treatment is finished. These results suggest 
that PKC-ε inhibition may inhibit other sources of reactive oxygen species activity to 
attenuate the quenching of constitutive blood NO levels. 
 
The role of PKC ε on regulation of eNOS activity on oxidative stress in ESWL 
 
 SO production in the blood which leads to increased levels of H2O2 can be 
produced by multiple sources, such as PMNs, endothelial NADPH oxidase, 
incomplete oxidative phosphorylation in mitochondria and uncoupled eNOS. Since 
the results in the study indicate that PKC-ε inhibitor, which is constitutively 
expressed only in ECs, decreased H2O2 levels to no-ESWL control levels, increased 
SO production in PMNs from NADPH oxidase can be ruled out. Since in the 
ischemia-reperfusion model, transmigrated PMNs did not release cytoxic substances 
until 30 minutes, PMNs were ruled out as a contributing factor to H2O2 release in 
ESWL-treated kidneys, and SO production was primarily attributed to EC enzymes 
such as endothelial NADPH oxidase and eNOS
61,73
. In the previous study, PKC-βII 
was inhibited, thus attenuating its activation of NADPH oxidase. However, in this 
study, since H2O2 level dropped to no-ESWL control levels, PKC-ε inhibitor 
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completely abolished SO production, suggesting that uncoupled eNOS is the primary 
producer of SO in the kidney rather than NADPH oxidase
73
. Because PKC-ε 
inhibition causes a dramatic difference in H2O2 and NO release, PKC-ε acts as a 
major operator in regulation of eNOS during oxidative stress post-ESWL. 
 
Future Studies 
 In order to assess whether there are increased leukocyte-endothelial 
interactions and the possibility of a subsequent inflammatory response, western blot 
and immunohistochemistry staining studies must be performed to determine an 
upregulation of proteins involved in leukocyte-endothelial reactions, such as P-
selectin, ICAM-1, and PECAM-1. The results from those studies will determine if 
prolonged vasoconstriction resultant of ESWL is an inflammatory response that can 
lead to damage of renal tissue. Future research will be directed towards investigating 
the effects of BH4, BH2, as well as BH4-to-BH2 ratio, to determine whether adjusting 
the cofactor status of eNOS would provide the same supportive effects towards NO 
bioavailability. PKC-ε activator and inhibitor will also be tested for pre-conditioning 
in the lithotripsy model, to gauge its effects before ESWL treatment and compare 
them to this study’s post-ESWL effects. Finally, high-performance liquid 
chromatography will be utilized to record the levels of BH2 and BH4, and the 
concentration ratio between the two pterins from both treated and non-treated kidneys 
to investigate their levels under conditions of oxidative stress, provide further 
evidence for eNOS uncoupling during oxidative stress, and the importance of a 
maintained BH4-to-BH2 ratio. 
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Significance of Findings 
Until the technology to improve imaging and targeting of kidney stones can be 
developed, treatment for damage from ESWL must rely upon refining the technique 
of ESWL delivery or pharmaceutical intervention. Although much research has been 
conducted on fine-tuning the ESWL delivery procedure, not much has been directed 
toward oxidative stress that may lead to underlying inflammatory response and cell 
damage. This study further confirms that even under the safer procedure guidelines, 
levels of H2O2 and NO indicate a decreased NO bioavailability and increased 
oxidative stress post-ESWL treatment. Our research has also found that eNOS is the 
principle target responsible for oxidative stress after lithotripsy.  The data from this 
study suggests beneficial effects of PKC-ε inhibitor may be due to inhibition of 
uncoupled eNOS activity and that uncoupled eNOS activity is the primary source of 
oxidative stress post-ESWL since PKC-ε inhibitor reduces H2O2 levels to near no-
ESWL levels. By using PKC-ε inhibitor after ESWL, the decreased oxidative stress 
can attenuate vascular endothelial dysfunction to the renal vasculature. This study 
suggests that PKC-ε inhibitor may be applied clinically post-ESWL to reduce 
vascular complications that can lead to development of hypertension.  
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